Researchers at the Icahn School of Medicine at Mount Sinai have made a promising breakthrough in the treatment of small cell ...

Ataxia telangiectasia develops in childhood ... In trials, this rapid progression could in theory help detect a treatment ...

An IgE deficiency was demonstrated in 11 of 16 patients with ataxia-telangiectasia. No relation to age or to the level of IgG, IgM or IgD was found. Nine out of 11 patients with IgE and IgA ...

Other patients who require follow-up are those with conditions associated with higher radiosensitivity e.g. ataxia telangiectasia ... early phase usually does not require any treatment, and frequently ...

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at ...

Repare Therapeutics said it received encouraging early phase 1 data for its camonsertib inhibitor combined with palliative radiation for the treatment of metastatic tumors harboring an ...

There is currently no cure for Friedreich’s ataxia. Treatment focuses on managing your symptoms and improving your quality of life to help you maintain your daily function and activities as long ...

Larimar Therapeutics' CTI-1601 offers hope for Friedreich's ataxia patients, with promising trial results. Check out why LRMR ...

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...

Repare Therapeutics said it received encouraging early phase 1 data for its camonsertib inhibitor combined with palliative radiation for the treatment of metastatic tumors harboring an ...

It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response ...

Repare Therapeutics said it received encouraging early phase 1 data for its camonsertib inhibitor combined with palliative radiation for the treatment of metastatic tumors harboring an ataxia ...